Results from two small clinical trials have shown that intradermal injection of the immune system–boosting agent CpG-B after surgery can reduce the recurrence risk for stage I/II melanoma. The study was presented at the 2015 International Cancer Immunotherapy Conference (abstract A050)
Conferences
Exosome Diagnostics’ Exosomal RNA Platform Demonstrates Enrichment of Tumor-Specific Gene Changes in Response to Immunotherapy Treatment
Exosome Diagnostics, Inc., a developer of revolutionary, biofluid-based molecular diagnostics, today announced new data demonstrating the novel ability of its proprietary exosomal RNA (exoRNA) technology platform to enrich cancer specific exosomes in order to more precisely determine tumor-specific gene changes in response to immunotherapy treatment.
New Preclinical Data Presented at SITC Annual Meeting Highlight Bavituximab’s Enhanced Anti-Tumor Activity When Combined With Checkpoint Inhibitors in Breast Cancer and Melanoma
Peregrine Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing therapeutics to stimulate the body’s immune system to fight cancer, today announced results from multiple new preclinical studies demonstrating enhanced anti-tumor activity and immune activation for combinations of a preclinical bavituximab equivalent and checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4 in preclinical models of breast cancer and melanoma. Additionally, the company announced preliminary results for a new clinical test specifically designed to illustrate how bavituximab, the company’s investigational phosphatidylserine (PS)-signaling pathway inhibitor, modulates immune responses in the tumor microenvironment. Results from these studies were presented at the 2015 annual meeting of the Society for Immunotherapy of Cancer (SITC), which was held in National Harbor, MD, on November 4 – 8, 2015.
PHARMAC asked to fast-track melanoma funding reviews
Summit calls for PHARMAC to fast track funding reviews for latest melanoma treatments
Melanoma experts are calling on PHARMAC to fast track funding reviews for the latest treatments for advanced melanoma, saying New Zealanders are missing out.